Biomedical, Clinical & Life Sciences

Apply to Internal Competition // Limit: 1 // Tickets Available: 1

Limiting Language
Only one application per institution (normally identified by having a unique UEI number) is allowed. As defined in the HHS Grants Policy Statement, applications received in response to the same NOFO generally are scored individually and then ranked with other applications under peer review in their order of relative programmatic, technical, or scientific merit. CDC/NIOSH will not accept any application in response to this NOFO that is essentially the same as one currently pending initial peer review unless the applicant withdraws the pending application.

Purpose
 
NIOSH is seeking applications from qualified organizations for a National Center for Construction Safety and Health Research and Translation (also known as the NIOSH National Construction Center). Applicants are expected to propose multi-disciplinary approaches for impactful applied and intervention research and hazard identification and controls, to develop partnerships for implementing prevention and intervention activities, and to serve as leaders in research translation and research-to-practice for the protection of construction workers in the United States. The NIOSH National Construction Center will accomplish these goals by 1) integrating and advancing research, 2) translating and disseminating best practices, 3) disseminating information, 4) informing policy, and 5) building capacity. Applicants must describe the occupational health and safety burden(s) addressed in their proposals. In addition, they must link the need for the proposed research and related activities to the planned outputs and outcomes that will help address or alleviate the construction sector burdens described. Applicants should also describe the anticipated impacts and potential outcomes of the proposed research and related activities that will occur during the 5-year project period and beyond.

Request Ticket // Limit: 1 // Tickets Available: 1 

Limiting Language
Only one application per institution (normally identified by having a unique entity identifier (UEI) number or NIH IPF number) is allowed.

Request Ticket // Limit: 1* (additional application possible for cancer types specified below) // Tickets Available: 1

Limiting Language

• Institutions may submit only one new fellowship application per year, with the exception noted in the next bullet allowing a possible second application. (Concurrent fellows with different funding periods are allowed.) 
• ATTENTION: limited submissions policy exception:  Due to high interest from donors and low numbers of past applications, a second Fellow application will be accepted only if focused on one of the following:   
  • Brain tumors – all types, including rare forms, especially atypical teratoid/rhabdoid tumor (AT/RT), diffuse intrinsic pontine glioma (DIPG)/diffuse midline glioma (DMG), and glioblastoma (GBM) 
  • Burkitt lymphoma – all types, especially sporadic 
  • Rhabdoid tumors - Extrarenal 
• NOTE: This exception to the limited submissions policy is valid whether or not your institution took advantage of the exception in another grant cycle. 

Program Overview/Select Eligibility Criteria
St. Baldrick’s Fellowships are granted for two (2) years of pediatric oncology fellowship training, with an opportunity for one (1) additional year of funding based upon need, significant accomplishment, and approved application. 

• During each grant cycle, an applicant can only apply once as the lead Principal Investigator.  
• Institutions must be located in the United States. 
• Applicants need not be American citizens; however, they must work at an academic, medical, or non-profit research institution within the United States. 
• Applicants from the NCI/NIH are not eligible to apply for St. Baldrick’s Fellowship Awards. 
• For Fellowship Awards, a program/institution is defined by the institution’s American Board of Pediatrics approved fellowship program in Pediatric Hematology/Oncology.  
• St. Baldrick’s funds may not be used for human embryonic stem cell research.
• Fellowship Awards are limited to salary and fringe benefits for the Fellow. • Applicants should hold an M.D. or D.O. degree by the date the grant becomes effective. 
• Applicant should be in their 2nd or 3rd year of pediatric oncology fellowship by July 1, 2027. Exceptions are allowed for a research residency format (2 years of residency 4 years of fellowship).  
  • If the applicant fits a research residency format exception, please state this in the applicant eligibility statement in the Letter of Intent. 
• Applicants may not hold an appointment of assistant professor or above. 
• Applicants must have a fellowship mentor who provides supervision, facilities, and research support at an American Board of Pediatrics approved fellowship program in Pediatric Hematology/Oncology. 
  • A co-mentor is allowed. 

The full request for proposals is linked here. 

Request Ticket // Limit: 1 // Tickets Available: 1

Limiting Language 
Only one proposal will be considered by ECA from each applicant organization. In cases where more than one submission from an applicant appears in grants.gov, ECA will only consider the submission made closest in time to the NOFO deadline; that submission would constitute the one and only proposal ECA would review from that applicant.

Executive Summary
The Office of Citizen Exchanges, Global Leaders Division, of the Bureau of Educational and Cultural Affairs (ECA) invites proposal submissions for the FY 2026 TechLeaders: Critical Emerging Technologies Program. TechLeaders will strengthen America’s technological edge and industry dominance by promoting U.S. leadership in Artificial Intelligence (AI), Space Technology, Biotechnology/Health Technology, Supply Chain/Cold Chain Technology, and Agricultural Technology (AgriTech). This initiative engages approximately 60 foreign participants, ages 25-40, from Europe and Eurasia, East Asia and the Pacific, Middle East and North Africa, South and Central Asia, Sub-Saharan Africa, and the Western Hemisphere through a five-week intensive placement in the United States. Participants will collaborate with U.S.- based mentors and companies to develop actionable solutions in critical technology sectors, showcasing American expertise and innovation. The program will also feature overseas components including reciprocal exchanges and an accelerator following the second U.S.-based cohort to expand U.S. influence, inspire future STEM professionals, and foster collaboration with American businesses. TechLeaders supports U.S. national security and foreign policy objectives byexporting American expertise and technological innovations abroad, promoting U.S.- preferred technology standards globally, bolstering economic ties, and countering the proliferation of malign competitors’ technology in the global market.

Organizations applying for this federal award must demonstrate the capacity to recruit, select, and place participants, manage all program logistics, and implement overseas programming, which includes annual reciprocal exchanges and a Critical Emerging Technologies Accelerator program after the second cohort of participants. The recipient will be awarded $ 1,500,000 for the overall FY 2026 TechLeaders: Critical Emerging Technologies Program, ensuring that taxpayer dollars are used efficiently to advance U.S. national interests and global leadership in criticaltechnology sectors.

Limit: 3 // Tickets Available: 0

G. Martin-Alemañy (Nutritional Sciences and Wellness)
B. Tanriover (COM-T)
S. Kharait (COM-T)

Limiting Language
A limit of three proposals from each sponsoring academic institution is imposed to enable fair and broad support for DCI-affiliated investigators.

Overview 
The Paul Teschan Research Fund (PTRF) of Dialysis Clinic, Inc. (DCI) offers grant support for research
related to human kidney disease. Research methods may range from basic science to clinical and
epidemiologic research. Support from this fund, named to honor Paul Teschan, MD, a distinguished
investigator, clinician and advisor to DCI, is intended to promote investigations of current or eventual clinical
significance that might not be able to achieve funding from NIH or other national sources because of their
clinical nature, their early stage of work, or other reasons. The PTRF is a source of funding for worthy
projects where other sources are unavailable.

A limit of three proposals from each sponsoring academic institution is imposed to enable fair and broad
support for DCI-affiliated investigators. Each individual grants are limited to $60,000 per year, including
institutional overhead. The funding period for PTRF research grants is Jan 1 – Dec 31. The initial award
installment is contingent on the project passing DCI’s legal, compliance and regulatory review. This includes
obtaining IRB or IACUC approvals. Subsequent installments are contingent upon adherence to the award
letter.

Preference will be given to earlier research career investigators and to projects considered most relevant
to understanding and treatment of clinical kidney conditions and their complications. All proposals will be
reviewed for scientific merit and significance by external reviewers and also by a panel of DCI-affiliated
nephrologists (Application Review Committee) as part of the competitive application process. Renewal of
ongoing PTRF funding projects is given preference, but is not automatic. Grant awards are merit based.
PTRF grants may not be used to fund salaries of investigators, but may support other personnel active in
the project as approved by DCI. Capital equipment costing $1500 or more may not be included in PTRF
budgets. Overhead is limited to 20% ($10,000). Travel may be requested in the budget during Year 2 and
Year 3 if work from the PTRF project is being presented at a conference, but this may not exceed $1500
per year. No travel will be supported by Year 1 funds. Projects will only be funded for one year at a time
and may be funded for a total of three (3) consecutive years. Year 2 and Year 3 applications will undergo
competitive review by the Application Review Committee for continued funding based on progress
described in a DCI PTRF Study Progress Report. Applications for Year 2 and Year 3 funding will be
reviewed in the same way as an initial application, including reassessment of the scientific merit of the work
proposed as well as the addition of a detailed review of the work accomplished. Grants may not be renewed
in the absence of progress satisfactory reports.

The University of Arizona is not eligible due to an existing award: A current recipient or applicant of the NIOSH T03, Occupational Safety and Health Training Project Grants award is not eligible for an award or a sub-award under this Funding Opportunity Announcement.

Apply to Internal Competition // Limit: 1 // Tickets Available: 1

The University of Arizona Cancer Center (UACC) is coordinating this limited submission. For more information please contact: UACC-PreAward.

Limiting Language
The University of Arizona Cancer Center (UACC) can nominate one applicant.

Purpose of Award:

The UACC is seeking nominations for the V Scholar Grant call which supports adult cancer research. This award supports tenure-track faculty early in their cancer research career by funding projects that are either laboratory-based fundamental research or translational research. The V Scholar Grant supports tenure-track faculty in the early stages of their independent cancer research careers. This grant mechanism is designed to advance exceptional early-career investigators at the Assistant Professor level and position them to successfully compete for larger, sustaining grants such as NIH R01 awards or equivalent funding.

Research on ANY adult cancer type will be funded in this call. Research areas not included in this scope are epidemiology, behavioral science, and health services research.

Award Amount:

• The total grant award is $800,000 over four years, with annual payments of $200,000. No indirect costs allowed.
• The V Foundation follows NIH Guidelines regarding salary caps. Institutions are welcome to supplement a grant recipient’s salary with institutional funds if desired.  

Applicant Eligibility:

Nominee must meet all of the following criteria by the nomination due date:

• Nominated by their Cancer Center Director or similar high ranking research official.
• Employed at a non-profit research institution (e.g., 501c3, Section 170).
• Either a US Citizen or a permanent legal resident in the US.
• Have completed at least two years postdoctoral (MD or PhD) fellowship training. For MDs, a minimum of one year is acceptable if one year is standard for their specialty
• Clinical scientists must have full institutional support (e.g., dedicated lab space, protected research time, start-up funds).
• Hold a full-time, tenure-track or tenured faculty position (e.g., eligible to apply as PI on an R01 at their institution). Non-promotable adjunct, affiliated, temporary, part-time, or acting faculty positions are not eligible.
• Have been appointed to their first full-time, tenure-track Assistant Professor position within five years of the nomination due date and not yet promoted to Associate Professor.
  • Extensions to the five-year limit may be granted on a case-by-case basis for nominees who have taken parental or other qualifying leave during this period.
  • To request approval before submitting the nomination form, email grants@v.org with the following information from your institution:
    • Appointment start date
    • Length and category of leave (e.g., medical, parental)

Limit: 3 // Tickets Available: 2

P. Madhivanan (Public Health)

Limiting Language
Applications are limited to three submissions per institution. Institutions may submit up to three applications for each Impact Grant track (research grants and fellowship projects and community projects). Institutions are defined by distinct EIN numbers. 

Executive Summary 
The Prevent Cancer Foundation® is the only U.S.-based nonprofit organization solely dedicated to cancer prevention and early detection. Our mission is empowering people to stay ahead of cancer through prevention and early detection. Our vision is a world where cancer is preventable, detectable and beatable for all.  

To advance the Prevent Cancer Foundation’s bold goal to reduce cancer deaths by 40% by 2035, we aim to support innovative research and vital community projects dedicated to increasing and advancing cancer prevention and early detection.  

The goal of the Prevent Cancer Foundation’s research program is to identify and provide funding for innovative projects with the potential to make substantial contributions to cancer prevention and/or early detection. By funding the most promising research, including fellowship projects led by early-career scientists, we contribute to important advances in cancer prevention and early detection.  

The Foundation funds research grants and fellowships at a broad range of academic institutions and cancer centers across the United States, including both well-established and rising institutions advancing cancer research.  


 

Limit: 1 // Tickets Available: 0 

J. Gaither (Emergency Medicine - COM-T) - competitive renewal

Limiting Language 
Eligible applicants may submit one application only to the FY 2026 funding opportunity. If multiple applications are received from the same political subdivision of a State and/or applicant, the last application submitted will be reviewed. If an applicant is eligible for both a Planning and Demonstration Grant and an Implementation Grant, the applicant must choose between applying for a Planning and Demonstration Grant or an Implementation Grant.  

Executive Summary
Funds for the fiscal year (FY) 2026 SS4A grant program are to be awarded on a competitive basis to support planning, infrastructure, and behavioral and operational initiatives to prevent fatalities and serious injuries on roads and streets involving all roadway users, including pedestrians, bicyclists, public transportation, motorists, and commercial vehicle operators.

 

Notify Limited Submissions if you plan to submit a full proposal, include the topic area and lab you plan to submit on behalf of (you must have submitted a solution summary) // Limit: One full proposal (TA1 or TA2) per lab. 

Limiting Language 
Participation in multiple proposals – Only a small fraction of solution summaries are expected to be encouraged for full proposal submissions. At the solution summary stage, proposing entities may submit separate solution summaries for TA1 and TA2 as the prime. However, at the full proposal stage, proposing entities may only submit one full proposal (either TA1 or TA2) as the prime. Proposing entities may be part of multiple full proposal submissions as subcontractors. In this context a ‘proposing entity’ is an academic lab, small business, or unit of a large business. Different labs with different PIs from the same academic institution are considered separate proposing entities.

Introduction
A growing body of evidence suggests that micro- and nano-plastics (MNPs) harm human health. The Systematic Targeting Of MicroPlastics (STOMP) program seeks to better quantify MNPs in humans; understand the mechanisms of MNP deposition; and, ultimately, improve human health by developing means to limit uptake and remove MNPs from the body.